(secondQuint)Single Arm, Open-label, Long-term Study of Romiplostim in Thrombocytopenic Pediatric Subjects With ITP.

.

 This is a phase 3b single arm, open label, multicenter study describing the percentage of time pediatric subjects with ITP have a platelet response while receiving romiplostim, defined as a platelet count 50 x 10^9/L and in the absence of ITP rescue medications in the past 4 weeks.

 This protocol will provide open label romiplostim to thrombocytopenic pediatric subjects with ITP diagnosed for at least 6 months and who have received at least 1 prior ITP therapy (excluding romiplostim) or are ineligible for other ITP therapies.

.

 Single Arm, Open-label, Long-term Study of Romiplostim in Thrombocytopenic Pediatric Subjects With ITP.

@highlight

This is a phase 3b single arm, open label, multicenter study describing the percentage of time pediatric subjects with ITP have a platelet response while receiving romiplostim, defined as a platelet count 50 x 10^9/L and in the absence of ITP rescue medications in the past 4 weeks.

